31 Jan

CollPlant Announces ADS Listing on NASDAQ

NESS ZIONA, IsraelJanuary 31, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that its American Depository Shares ("ADSs") have been approved for listing on The Nasdaq Capital Market. Trading commenced on Wednesday, January 31, 2018 under the ticker symbol "CLGN". In addition, and simultaneously, Collplant's ordinary shares will continue to trade on the Tel-Aviv Stock Exchange market (TASE: CLPT).
Yehiel Tal, CEO of CollPlant stated "We believe the Nasdaq listing gives us the opportunity to increase the trading liquidity of our securities, broaden our shareholder base and significantly raise our profile in the investment community. CollPlant's proprietary product line addresses indications for a diverse fields of organ and tissue repair, and is making a real impact in the field of regenerative medicine. Our flagship rhCollagen BioInk product offering is being developed for 3D bioprinting of tissues and organs, and our Vergenix line of rhCollagen products includes a soft tissue repair matrix for the treatment of tendinopathy, as well as a wound repair matrix to promote rapid, optimal healing of acute and chronic wounds. Trading of CollPlant's ADSs on Nasdaq is a natural extension of our growth goals." About CollPlant CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix®STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix®FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant's business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products. For more information about CollPlant, visit http://www.collplant.com Forward-Looking Statements This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Collplant's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Collplant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Collplant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which we operate; projected capital expenditures and liquidity; changes in our strategy; our ability to cooperate with third party collaborators; government regulations and approvals; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting Collplant is contained under the heading "Risk Factors" included in Collplant's most recent registration statement on Form F-1 filed with the SEC on January 29, 2018, and in other filings that Collplant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Collplant's current views with respect to future events, and Collplant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact at CollPlant: Eran Rotem Deputy CEO & Chief Financial Officer Tel: +972-73-2325600/612 Email: Eran@collplant.com Contact at Rx Communications Group, LLC: Paula Schwartz (for US Investors) Managing Director Tel: 917-322-2216 Email: pschwartz@rxir.com SOURCE CollPlant

Read More
31 Jan

Camber Spine Reports Strong Performance Results for 2017

WAYNE, Pa.Jan. 31, 2018 /PRNewswire/ -- Camber Spine, a leading innovator in spine and medical technologies, today reports a strong finish to 2017 with record fourth quarter sales and year-over-year growth. 2017 was by all accounts a very strong year for Camber Spine with 54.2% growth in Q4 and 46% year-over-year growth largely driven by an increase of 97% of active surgeon users in the past 12 months. "We attribute our sizable growth directly to expansion of our sales team and significant additions to our product portfolio," said Daniel Pontecorvo, CEO. "In 2017 Camber made a big investment with the addition of very talented area directors which have enabled us to expand into additional markets across the country. This past year also saw the launch of three new products, Ti-Diagon™ Anatomic Oblique TLIF, SPIRA™ Open Matrix ALIF and SPIRA-C™ Open Matrix Cervical Interbody." SPIRA™ ALIF and SPIRA™-C are part of the SPIRA™ proprietary technology platform of spinal implants that feature SURFACE BY DESIGN™ together with the SPIRA™ open architecture arched design which enables the goal of endplate-to-endplate fusion and long-term stability. "As we look ahead to the future, we anticipate a strong 2018 with the planned launch of three exceptional new products – the second generation of ENZA™ MIS ALIF, SPIRA™-L Open Architecture Lateral Cage and SPIRA™V Open Matrix Corpectomy. We have an active product development pipeline and expect submission and approval of 6 new products for FDA clearance this year." About Camber Spine Camber Spine Technologies, LLP, is a medical device company focused on the design, development and commercialization of innovative and proprietary musculoskeletal implant systems. The company is committed to delivering surgeon inspired new technologies to the spine market.  Camber Spine, located in Wayne, Pennsylvania, markets a line of proprietary musculoskeletal products nationwide through its exclusive distributor, S1 Spine. All of Camber Spine's products are proudly MADE IN THE USA. www.cambermedtech.com SOURCE Camber Spine

Read More
31 Jan

IMPLANET: Update on the L&K BIOMED Partnership

January 30, 2018

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible; OTCQX: IMPZY) (Paris:ALIMP) (OTCQX:IMPZY), a medical technology company specializing in vertebral and knee-surgery implants has released a progress update on the partnership it entered into with South Korean company L&K BIOMED Co. Ltd in December 2017. On December 6, IMPLANET announced it had entered into a preliminary agreement concerning the implementation of a worldwide partnership with L&K BIOMED in order to accelerate its expansion, especially in the United States and in Asia. The distribution agreement with AEGIS SPINE, L&K BIOMED’s US subsidiary, has now been completed, in line with previous announcements. IMPLANET will capitalize on the expertise of Aegis Spine to complement the existing commercialization efforts in the United States, the company’s priority market. The first surgeries with AEGIS SPINE’s KOLs are scheduled for early February. In conjunction, both companies’ Asian and European teams are working on regulatory, marketing and commercial aspects of the two product line launches in their respective markets. L&K BIOMED’s technical and sales teams will undergo training at IMPLANET’s headquarters in early February. Cross-distribution agreements covering these geographical territories are due to be signed in the next few weeks. Next financial press release: full-year 2017 results on Thursday, March 14, 2018 About IMPLANET Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com. Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80 Disclaimer This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company's website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.

Contacts

IMPLANET Ludovic Lastennet, Tel. : +33 (0)5 57 99 55 55 CEO investors@implanet.com or NewCap Investor Relations Julie Coulot, Tel. : +33 (0)1 44 71 20 40 implanet@newcap.eu or NewCap Media Relations Nicolas Merigeau, Tel. : +33 (0)1 44 71 94 98 implanet@newcap.eu or AlphaBronze US-Investor Relations Pascal Nigen, Tel.: +1 917 385 21 60 implanet@alphabronze.net

Read More
31 Jan

Zimmer Biomet Announces Fourth Quarter and Full-Year 2017 Results

WARSAW, Ind.Jan. 30, 2018 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and full year ended December 31, 2017.  The Company reported fourth quarter net sales of $2.074 billion, an increase of 3.0% over the prior year period, and an increase of 1.5% on a constant currency basis.  Diluted earnings per share for the fourth quarter were $6.16, and include a one-time tax benefit of approximately $6.40 resulting from the recently enacted U.S. tax reform legislation.  Fourth quarter adjusted diluted earnings per share were $2.10, a decrease of 1.9% from the prior year period. Full-year 2017 net sales were $7.824 billion, an increase of 1.8% over the prior year, on both a reported and constant currency basis.  Full-year revenues increased by 0.5% over the prior year on a constant currency basis, excluding approximately 130 basis points of contribution from the LDR Holding Corporation acquisition.  Diluted earnings per share for the full year were $9.03.  Adjusted diluted earnings per share for the full year were $8.03, an increase of 0.9% over the prior year. Bryan Hanson, President and CEO of Zimmer Biomet, said: "Since joining the Company last month, I have been performing a thorough review of the business.  My immediate priorities are to improve Zimmer Biomet's execution and address a number of near-term challenges that have impacted, and will continue to impact, our performance.  With that said, I fully believe in the power of the Zimmer Biomet global brand and portfolio of products, and I am confident that with sound strategy and enhanced execution we can drive sustained shareholder value." Net earnings for the fourth quarter were $1.257 billion, and $428.5 million on an adjusted basis.  Operating cash flow for the fourth quarter was $402.9 million. Net earnings for full-year 2017 were $1.840 billion, and $1.636 billion on an adjusted basis. In the quarter, the Company paid $48.6 million in dividends and declared a fourth quarter dividend of $0.24 per share.  The Company also repaid $300.0 million of debt during the quarter.  For full-year 2017, the Company paid $193.6 millionin dividends and repaid approximately $1.250 billion of debt. (1) U.S. tax reform legislation resulted in a net favorable provisional adjustment due to the reduction of certain deferred tax liabilities which were partially offset by provisional tax charges related to the toll tax provision of U.S. tax reform. The amount recognized is a provisional estimate and subject to change, possibly materially, due to, among other things, refinements of the Company's calculations, changes in interpretations and assumptions the Company has made or additional guidance issued by the U.S. Treasury, Securities and Exchange Commission or Financial Accounting Standards Board. Guidance For the first quarter of 2018, the Company expects revenue in the range of $1.955 billion to $1.995 billion, representing a change of negative 1.0% to positive 1.0% compared to the prior year period, and negative 4.0% to negative 2.0% on a constant currency basis compared to the prior year period, inclusive of negative impact related to approximately one less billing day compared to the prior year period. Additionally, the Company expects its diluted earnings per share for the first quarter of 2018 to be in a range of $0.73 to $0.88, and in a range of $1.84 to $1.91 on an adjusted basis. Conference Call The Company will conduct its fourth quarter and full-year 2017 investor conference call today, January 30, 2018, at 8:00 a.m. Eastern Time.  The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at http://investor.zimmerbiomet.com. It will be archived for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (888) 312-9837 and entering conference ID 7278985.  For a complete listing of international toll-free and local numbers, please visit http://investor.zimmerbiomet.com.  A digital recording will be available 24 hours after the completion of the conference call, from January 31, 2018 to March 1, 2018.  To access the recording, U.S. callers should dial (888) 203-1112 and international callers should dial +1 (719) 457-0820, and enter the Access Code ID 7278985. Sales Tables The following fourth quarter and full-year sales tables provide results by geography and product category, as well as the percentage change compared to the prior year periods on a reported basis and a constant currency basis.

NET SALES - THREE MONTHS ENDED DECEMBER 31, 2017 (in millions, unaudited)

Constant

Net

Currency

Sales

% Change

% Change

Geographic Results

Americas

$

1,280

0.9

%

0.8

%

EMEA

473

6.4

(0.3)

Asia Pacific

321

7.0

7.2

Total

$

2,074

3.0

%

1.5

%

Product Categories

Knees

Americas

$

443

(0.3)

%

(0.5)

%

EMEA

181

10.0

3.9

Asia Pacific

107

(4.1)

(4.4)

Total

731

1.4

(0.1)

Hips

Americas

256

0.8

0.5

EMEA

137

1.5

(5.3)

Asia Pacific

106

13.8

14.6

Total

499

3.5

1.6

S.E.T *

454

5.9

4.6

Dental

108

2.1

(0.4)

Spine & CMF

194

1.5

0.5

Other

88

4.3

2.9

Total

$

2,074

3.0

%

1.5

%

* Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

NET SALES - YEAR ENDED DECEMBER 31, 2017 (in millions, unaudited)

Constant

Net

Currency

Sales

% Change

% Change

Geographic Results

Americas

$

4,866

1.3

%

1.2

%

EMEA

1,745

0.9

0.2

Asia Pacific

1,213

5.4

6.3

Total

$

7,824

1.8

%

1.8

%

Product Categories

Knees

Americas

$

1,660

(1.7)

%

(1.7)

%

EMEA

644

1.0

0.9

Asia Pacific

433

1.5

1.6

Total

2,737

(0.6)

(0.6)

Hips

Americas

$

975

(1.2)

(1.3)

EMEA

519

(0.7)

(1.8)

Asia Pacific

385

7.5

9.1

Total

1,879

0.6

0.6

S.E.T *

1,709

3.9

4.0

Dental

419

(2.2)

(2.6)

Spine & CMF

759

14.7

14.4

Other

321

(2.5)

(2.6)

Total

$

7,824

1.8

%

1.8

%

* Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma

About the Company Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet. Website Information We routinely post important information for investors on our website, www.zimmerbiomet.com, in the "Investor Relations" section.  We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.  Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document. Note on Non-GAAP Financial Measures This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP").  These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP. Sales change information for the three-month period and the year ended December 31, 2017 is presented on a GAAP (reported) basis and on a constant currency basis.  The sales change information for the full year is also presented on a constant currency basis that excludes the contribution from the Company's acquisition of LDR Holding Corporation in July 2016.  Projected revenue change information is also presented on a GAAP basis and on a constant currency basis.  Constant currency rates exclude the effects of foreign currency exchange rates.  They are calculated by translating current and prior-period sales at the same predetermined exchange rate.  The translated results are then used to determine year-over-year percentage increases or decreases. Net earnings, diluted earnings per share and projected diluted earnings per share are presented on a GAAP (reported) basis and on an adjusted basis.  Adjusted earnings and adjusted diluted earnings per share exclude the effects of inventory step-up; certain inventory and manufacturing-related charges connected to discontinuing certain product lines, quality enhancement and remediation efforts; special items; intangible asset amortization; certain claims; goodwill impairment; debt extinguishment charges; any related effects on our income tax provision associated with these items; the effect of U.S. tax reform; and other certain tax adjustments.  Special items include expenses resulting directly from our business combinations and/or global restructuring, quality and operational excellence initiatives, including employee termination benefits, certain contract terminations, consulting and professional fees, dedicated project personnel, asset impairment or loss on disposal charges, certain litigation matters, costs of complying with our deferred prosecution agreement and other items.  Other certain tax adjustments include a tax restructuring that lowered the tax rate on deferred tax liabilities recorded on intangible assets recognized in acquisition-related accounting, net favorable resolutions of various tax matters, a favorable tax rate change in a foreign jurisdiction and charges from internal restructuring transactions that provide the Company access to cash in a tax efficient manner. Management uses these non-GAAP financial measures internally to evaluate the performance of the business and believes they are useful measures that provide meaningful supplemental information to investors to consider when evaluating the performance of the Company.  Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported operating results, to perform trend analysis, to better identify operating trends that may otherwise be masked or distorted by these types of items and to provide additional transparency of certain items.  In addition, certain of these non-GAAP financial measures are used as performance metrics in the Company's incentive compensation programs. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in this press release.   READ THE REST HERE  

Read More
30 Jan

Medicrea Reports Directors’ Dealings Disclosure

January 30, 2018

LYON, France & NEW YORK--(BUSINESS WIRE)--The MEDICREA Group (Euronext Growth: FR0004178572 – ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD® ASI technology, announces transactions on securities of the Company by its Chairman and Chief Executive Officer. In accordance with Article 19 of Regulation (EU) No 596/2014 of April 16th, 2014, the Company has declared to the AMF the acquisition of 90,045 shares between January 22nd and 25th, 2018 by its Chairman and Chief Executive Officer, Denys Sournac. About Medicrea (www.Medicrea.com) Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 40 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants. Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 150,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room. For further information, please visit: www.medicrea.com

Connect with Medicrea: FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on EURONEXT Growth Paris ISIN: FR 0004178572 Ticker: ALMED LEI: 969500BR1CPTYMTJBA37

Contacts

Medicrea Denys Sournac Founder, Chairman and CEO dsournac@Medicrea.com or Fabrice Kilfiger, +33 (0)4 72 01 87 87 Chief Financial Officer fkilfiger@Medicrea.com

Read More
30 Jan

Misonix to Report Fiscal 2018 Second Quarter Financial Results, Host Conference Call and Webcast on February 6

FARMINGDALE, N.Y., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it will report its fiscal 2018 second quarter financial results after the market closes on Tuesday, February 6, 2018. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the general public.

To access the conference call, interested parties may dial 800/281-7973 (domestic) or 323/794-2093 (international) conference ID 1246600.  Participants may also listen to a live webcast of the call through the “Events and Presentations” section under “Investor Relations” on Misonix’s website at www.misonix.com. A webcast replay will be available for 30 days following the live event at www.misonix.com.

Please call five minutes in advance to ensure that you are connected. Questions and answers will be taken only from participants on the conference call. For the webcast, please allow 15 minutes to register, download and install any necessary software.

About Misonix, Inc. Misonix, Inc. (Nasdaq:MSON) designs, develops, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix's proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s 59-year history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.

Contact: Joe Dwyer Chief Financial Officer Misonix, Inc. 631-694-9113 Joseph Jaffoni, Norberto Aja, Jennifer Neuman JCIR 212-835-8500 or mson@jcir.com

Read More
30 Jan

Study Shows Patients with MicroPort’s Medial-Pivot Knee Are More Likely to Forget They’ve Had a Joint Replacement

January 30, 2018

ARLINGTON, Tenn.--(BUSINESS WIRE)--MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced that The Journal of Arthroplasty has published a retrospective, comparative study that evaluated patient satisfaction after total knee arthroplasty (TKA) using the MicroPort Orthopedics’ MicroPort Orthopedics’ Evolution® Medial-Pivot (MP) Knee System. The study showed that patients who underwent the MP-TKA scored significantly better on the Forgotten Joint Score (FJS) than those who underwent the PS-TKA, particularly with regard to deep knee flexion and stability of the prosthesis. “The goal of TKA surgery is to provide a joint replacement that functions as closely as possible to a normal knee and I believe that this study further validates the superiority of the medial-pivot design over traditional designs with regard to patient outcomes,” says David Backstein, MD, MEd, FRCSC, Head of Orthopaedic Surgery at Mount Sinai Hospital in Toronto, Ontario. “MicroPort’s medial-pivot features an insert designed to promote medial stability and lateral mobility and a femoral component with constant radii of curvature, resulting in greater stability and kinematics that closely replicate the natural motion of the knee.” The article titled, “A Retrospective Comparison of a Medial Pivot and Posterior-Stabilized Total Knee Arthroplasty with Respect to Patient-Reported and Radiographic Outcomes,” was authored by Drs. David Samy and David Backstein from the Granovsky Gluskin Division of Orthopaedics at University of Toronto. A total of 164 patients, 76 in the MP-TKA group and 88 in the PS-TKA group, were evaluated at one-year follow-up using the FJS, a recently developed, validated measure of patient satisfaction after TKA. The FJS score is based on a 12-item questionnaire related to patients’ ability to forget their artificial joint in everyday life. To date, this study is the first to compare an MP-TKA and a PS-TKA using the FJS as a primary outcome measure. Studies show that around 20 percent of patients are not satisfied with the outcome of their total knee replacement as a result of residual pain and functional issues that can often attributed to implant design1. Based on the results of this study as well as previous studies showing 95% patient satisfaction and 98.8% survivorship at 17 years, it is clear that the unique design of the MP-TKA can deliver reproducible outcomes that drive patient satisfaction2. Furthermore, it is the only medial-pivot system on the market with a clinically-proven 20-year history. About MicroPort Orthopedics Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/. About MicroPort Scientific MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 20 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com. Forward-Looking Statements Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China. This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever. Sources:

1. Thambiah, Matthew Dhanaraj et al. “Patient Satisfaction after Total Knee Arthroplasty: An Asian Perspective.” Singapore Medical Journal 56.5 (2015): 259–263. 2. Macheras, George A. et al. “A long term clinical outcome of the Medial Pivot Knee Arthroplasty System.” The Knee 24 (2017): 447-453.

Contacts

LaVoie HealthScience Sharon Correia, 617-412-8779 scorreia@lavoiehealthscience.com

Read More
29 Jan

Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The total net proceeds of the offering are approximately $5.9 million after deducting the underwriting discounts and commissions payable by Histogenics.

Canaccord Genuity acted as the sole book-running manager for the offering.

A shelf registration statement on Form S-3 (File No. 333-216741) relating to the underwritten registered direct offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the SEC) and declared effective by the SEC on March 30, 2017. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on January 24, 2018 and is available on the SEC’s web site at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, by telephone at (617) 371-3900, or by email at prospectus@canaccordgenuity.com.

About Histogenics Corporation

Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function.  Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and potentially prevent a patient’s progression to osteoarthritis.  NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use.  Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018.  NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.


Read More
29 Jan

Bone Solutions Inc. Reaches 50 Implants Of Its Proprietary Magnesium-Based Bone Void Filler

“This milestone is a huge accomplishment for our company, and we’re excited to continue to introduce our product to surgeons around the country,” says BSI president and CEO Drew Diaz.

The OsteoCrete® implants were performed by various surgeons in the U.S. during BSI’s 90-day launch period, which ran from October 1 to December 31, 2017. The company worked with a network of distributors to deliver and implement the product. BSI will now shift its focus to attaining approvals at various hospital systems in the U.S.

OsteoCrete® is the only bone-repair product in the market made with magnesium. This gives surgeons an advantage as compared to using calcium-based devices, which do not have the unique combination of compressive strength and expandability necessary for optimal binding quality. OsteoCrete® is resorbable, or capable of being assimilated back into the body, as it is replaced with bone as the patient heals. It’s also injectable, moldable, and biocompatible.

“I am confident 2018 will be a banner year for the company, and we look forward to the continued growth of both the market and the use of OsteoCrete® in future surgical applications,” says Diaz.

About Bone Solutions Inc. Bone Solutions Inc. (‘BSI’) (http://www.bonesolutionsinc.com) is an orthobiologics company with a vision to provide orthopedic surgeons a means to improve clinical outcomes in a number of complex procedures while lowering costs. The company is revolutionizing a new solution for orthopedic surgeons for human uses with their FDA-cleared magnesium-based platform bone void filler.

Media Contact:

Bone Solutions Inc.: Drew Diaz President/CEO 817-809-8850 diaz(at)bonesolutions(dot)net

Read More
29 Jan

New Study on Total Hip Arthroplasty (THA) Outcomes with Anterior Approach Show Less Reported Pain, Fewer Narcotics and Better Hip Function in the First 90 Days

WARSAW, Ind.Jan. 29, 2018 /PRNewswire/ -- DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies, today announced the first systematic review of prospective studies comparing postoperative outcomes through 90 days of Anterior Approach versus Posterior Approach in primary total hip arthroplasty (THA). The paper, published in The Journal of Arthroplasty, concludes that the Anterior Approach can provide a significant increase in hip function and reduction in pain and narcotics usage compared to Posterior Approach. In addition, the study showed no statistical differences in complication rates between the Anterior Approach and Posterior Approach through 90 days. Previous comparative reviews of Anterior Approach versus Posterior Approach have predominantly relied on data from retrospective studies. For this meta-analysis, a total of 13 prospective comparative studies (including 7 randomized studies) published between 2006 and 2017 of more than 1,000 patients treated with Anterior Approach or Posterior Approach were included. Focused on perioperative outcomes, the meta-analysis attempted to address each component of the Comprehensive Care for Joint Replacement (CJR) model, which includes complication rate, patient satisfaction, and pain management over a 90-day period. The research was performed by Drs. Friedrich BoettnerJoseph S. Gondusky, and Atul F. Kamath** and well-known meta-analyst Dr. Larry E. Miller. Co-authors of the paper included Samir Bhattacharyya, PhD, MS, MSc, U.S. Head for Health Economics and Market Access (HEMA) DePuy Synthes and Dr. John Wright, Medical Leader DePuy Synthes. "Our goal with this research was to rigorously evaluate outcomes of Anterior Approach and Posterior Approach from the highest quality prospective studies performed to date," said lead author Dr. Miller. "We found that THA using the Anterior Approach provided clinically important benefits to patients compared to Posterior Approach over 90 days follow-up." The move toward the Anterior Approach is increasing as seen in a 2016 American Association of Hip and Knee Surgeons (AAHKS) survey where 34 percent of surgeons reported they were performing the Anterior Approach compared to 26 percent in a 2015 AAHKS survey. In an effort to gather additional data on this trend, DePuy Synthes, which funded this study, sought to understand the short-term benefits of the Anterior Approach as surgeons look for options in treating their patients. DePuy Synthes has spent more than a decade supporting healthcare providers who are interested in adding the Anterior Approach to their practices through professional education and training, and bringing enabling technologies to market. "While the Posterior Approach is still the most widely used technique worldwide, we see growing interest in the Anterior Approach," said Bhattacharyya. "This study builds on the mounting evidence that the Anterior Approach supports the goals of improving outcomes, optimizing the patient experience and reducing the overall cost of care." The study, "Does Surgical Approach Affect Outcomes in Total Hip Arthroplasty Through 90 Days of Follow-Up? A Systematic Review with Meta-Analysis," is available online and will appear mid-2018 in the Journal of Arthroplasty. About DePuy Synthes DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies***, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com. *DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates. **Drs. Friedrich BoettnerJoseph S. Gondusky, and Atul F. Kamath are consultants to DePuy Synthes Joint Reconstruction. ***The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson's Medical Devices segment. ©DePuy Synthes 2018. All rights reserved. DSUS/JRC/0118/2539 SOURCE DePuy Synthes

Related Links

http://www.depuysynthes.com

Read More